CYTOVIA

As of January 4, 2006, Cytovia, Inc. was acquired by EpiCept Corporation as a result of its acquisition of Maxim Pharmaceuticals. Cytovia, Inc., a development stage biopharmaceutical research company, engages in the discovery and development of small molecule inhibitors and activators of caspases. The company’s apoptosis inhibitors, activators, and novel drugs modulate programmed cell death. Its technology base includes proprietary drug candidates in the areas of oncology, oral mucositis, and cardiovascular disease, as well as a proprietary screening process for other apoptosis targeted drug candidates. The company was formed in 1997 and is based in San Diego, California. The company operated as a subsidiary of Maxim Pharmaceuticals, Inc. since June 16, 2000.